AEGIRBIO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.54 SEK | -3.40% |
|
-22.19% | -53.85% |
| Apr. 09 | AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas | MT |
| Apr. 09 | AegirBio Chairman to Resign | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.
Calendar
2024-05-16
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -53.85% | 1.57M | |
| +2.02% | 209B | |
| +2.17% | 177B | |
| +10.45% | 133B | |
| +16.62% | 99.89B | |
| -2.70% | 61.83B | |
| +13.38% | 52.51B | |
| -6.33% | 45.54B | |
| -4.74% | 39.43B | |
| +9.89% | 38.87B |
- Stock Market
- Equities
- AEGIR Stock
- News AegirBio AB
- AegirBio Shares Gain 13% on Approval to Prolong Shelf Life of COVID-19 Antigen Tests
